Celldex Therapeutics Inc (NASDAQ:CLDX) shares, rose in value on Friday, March 07, with the stock price down by -3.09% to the previous day’s close as strong demand from buyers drove the stock to $20.67.
Actively observing the price movement in the last trading, the stock closed the session at $21.33. Referring to stock’s 52-week performance, its high was $49.65, and the low was $18.61. On the whole, CLDX has fluctuated by -13.84% over the past month.
With the market capitalization of Celldex Therapeutics Inc currently standing at about $1.37 billion, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.08M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CLDX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CLDX currently trading nearly -4.01% and -11.81% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 41.34, while the 7-day volatility ratio is showing 8.01% which for the 30-day chart, stands at 5.64%. Furthermore, Celldex Therapeutics Inc (CLDX)’s beta value is 1.53, and its average true range (ATR) is 1.26.
A comparison of Celldex Therapeutics Inc (CLDX) with its peers suggests the former has fared considerably weaker in the market. CLDX showed an intraday change of -3.09% in last session, and over the past year, it shrunk by -58.67%%.
Data on historical trading for Celldex Therapeutics Inc (NASDAQ:CLDX) indicates that the trading volumes over the past 3 months, they’ve averaged 910.50K. According to company’s latest data on outstanding shares, there are 66.37 million shares outstanding.
Nearly 2.54% of Celldex Therapeutics Inc’s shares belong to company insiders and institutional investors own 109.69% of the company’s shares. The stock has fallen by -18.20% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CLDX stock heading into the next quarter.
